Guys & St Thomas NHS Foundation Trust, United Kingdom
Guys & St Thomas NHS Foundation Trust, United Kingdom

Time filter

Source Type

Global Metabolomics Market by Detection and Separation Techniques, and Applications, Growth Trends and Forecast to 2021, by iHealthcareAnalyst, Inc. Metabolomics Market by Detection and Separation Techniques, and Applications (Biomarker Discovery, Clinical Toxicology, Drug Assessment, and Nutrigenomics) and Forecast 2017-2021 Maryland Heights, MO, April 15, 2017 --( Browse Metabolomics Market by Detection and Separation Techniques, and Applications (Biomarker Discovery, Clinical Toxicology, Drug Assessment, and Nutrigenomics) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/ The global metabolomics market report estimates the market size (Revenue USD million - 2014 to 2021) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2017 to 2021). The global metabolomics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global metabolomics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global metabolomics market and included in this report are Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Shimadzu Corporation, and Waters Corporation. 1. Technique 1.1. Detection Techniques 1.2. Separation Techniques 2. Application 2.1. Biomarker Discovery 2.2. Clinical Toxicology 2.3. Drug Assessment 2.4. Nutrigenomics 3. Geography (Region, Country) 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profiles 4.1. Agilent Technologies Inc. 4.2. Biocrates Life Sciences AG 4.3. Bio-Rad Laboratories, Inc. 4.4. Bruker Corporation 4.5. Human Metabolome Technologies Inc. 4.6. LECO Corporation 4.7. Metabolon Inc. 4.8. Shimadzu Corporation 4.9. ThermoFisher Scientific Inc. 4.10. Waters Corporation To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/metabolomics-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 15, 2017 --( PR.com )-- Metabolomics is the scientific study of chemical processes involving metabolites, whereas metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes. mRNA gene expression data and proteomic analyses reveal the set of gene products being produced in the cell, data that represents one aspect of cellular function including systems biology and functional genomics that integrates proteomic, transcriptomic, and metabolomic information to provide a better understanding of cellular biology. Metabolomics is an advanced, specialized form of analytical biochemistry that involves the study of chemical processes involving metabolites. Metabolomics enables simultaneous identification and analysis of multiple metabolites in cells, tissues and body fluids. The research funding for metabolomics has increased over the years in the major areas of research includes characterization and identification of novel biomarkers, therapeutic targets, and disease signatures in the area of cancer metabolomics.Browse Metabolomics Market by Detection and Separation Techniques, and Applications (Biomarker Discovery, Clinical Toxicology, Drug Assessment, and Nutrigenomics) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/The global metabolomics market report estimates the market size (Revenue USD million - 2014 to 2021) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2017 to 2021). The global metabolomics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global metabolomics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global metabolomics market and included in this report are Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Shimadzu Corporation, and Waters Corporation.1. Technique1.1. Detection Techniques1.2. Separation Techniques2. Application2.1. Biomarker Discovery2.2. Clinical Toxicology2.3. Drug Assessment2.4. Nutrigenomics3. Geography (Region, Country)3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profiles4.1. Agilent Technologies Inc.4.2. Biocrates Life Sciences AG4.3. Bio-Rad Laboratories, Inc.4.4. Bruker Corporation4.5. Human Metabolome Technologies Inc.4.6. LECO Corporation4.7. Metabolon Inc.4.8. Shimadzu Corporation4.9. ThermoFisher Scientific Inc.4.10. Waters CorporationTo request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/metabolomics-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


FORT LAUDERDALE-DAVIE, FL--(Marketwired - October 24, 2016) - In recognition of his significant contributions to Nova Southeastern University (NSU), Robert C. Speth, Ph.D., was named the recipient of the Sixth Annual Provost's Research and Scholarship Award. Dr. Speth is a researcher and professor of pharmaceutical sciences in NSU's College of Pharmacy. Ralph V. Rogers Jr., Ph.D., NSU executive vice president and provost, made the special announcement at the university's External Funding Recognition Reception, hosted by Gary S. Margules, Sc.D., NSU vice president of Research and Technology Transfer, at which faculty members from all disciplines across the university are recognized for their commitment to advancing their fields of study. The Provost's Award honors a faculty member who has demonstrated significant achievement in support of NSU's mission to foster scholarship, intellectual inquiry, and academic excellence. Research and scholarship are two of NSU's eight core values, and excellence in these areas enhances education, patient care, and public service, and develops superior scholarship. "Dr. Speth has distinguished himself as a researcher, an educator, and a staunch supporter of the NSU community," said Dr. Rogers. "He has truly demonstrated what this award is meant to recognize: innovative and sustained activities in support of NSU's mission to foster intellectual inquiry, academic excellence, research and a dynamic learning environment." "This is the greatest honor that has ever been bestowed upon me," said Dr. Speth. "What makes it even greater is the fact that there are so many other incredibly talented faculty members in the NSU family who are also deserving of this recognition. I dedicate this award to my mentor Hank Yamamura who taught me to always make the best interests of my students my highest priority, and it is those very same students who paved the way for me to receive this honor." Dr. Speth is widely recognized for his research on how angiotensin acts in the brain to regulate the cardiovascular system. In the course of his career, he has secured more than $1 million in funding for his research through 22 externally-funded projects. Dr. Speth is a regular contributor to a variety of national publications and has served or is currently serving on the editorial boards of prestigious journals, including Regulatory Peptides, the Journal of Pharmacology & Clinical Toxicology and the International Journal of Peptides. He has served as an ad-hoc reviewer for 39 journals, including Science. He has also served the field as a grant reviewer for organizations including the American Heart Association, National Institutes of Health and National Science Foundation. Dr. Speth manages to be a leader in the research field while also offering countless hours to teaching endeavors. In addition to his classroom commitments, he has mentored countless high-school, undergraduate and graduate students, along with junior faculty members, working with him in his lab on various projects. Dr. Speth and his wife, Janet, are Bronze members of NSU's Fellows Society which recognizes individuals, corporations, and trusts who have made cumulative gifts of $100,000-$249,999. This demonstrates Dr. Speth's investment in the advancement of NSU through the largest philanthropic campaign in its history, Realizing Potential, which aims to raise $250 million for student, faculty and 21st century education initiatives, with research integral to all three priorities. Dr. Speth has received multiple honors, including election as a fellow of the American Association for the Advancement of Science. He earned his Ph.D. in Pharmacology from Vanderbilt University in Nashville, Tennessee, his Master of Arts degree in Physiological Psychology from Connecticut College in New London, and his Bachelor of Arts degree in Biology and Psychology from Western Maryland College in Westminster (now McDaniel College). *Denotes titles and college names at the time the award was presented. About Nova Southeastern University (NSU): Located in beautiful Fort Lauderdale, Florida, Nova Southeastern University (NSU) is a dynamic research institution dedicated to providing high-quality educational programs at the undergraduate, graduate, and first-professional degree levels. A private, not-for-profit institution, NSU has campuses in Fort Lauderdale, Fort Myers, Jacksonville, Miami, Miramar, Orlando, Palm Beach, and Tampa, Florida, as well as San Juan, Puerto Rico, while maintaining a presence online globally. For more than 50 years, NSU has been awarding degrees in a wide range of fields, while fostering groundbreaking research and an impactful commitment to community. Classified as a research university with "high research activity" by the Carnegie Foundation for the Advancement of Teaching, NSU is 1 of only 50 universities nationwide to also be awarded Carnegie's Community Engagement Classification, and is also the largest private, not-for-profit institution in the United States that meets the U.S. Department of Education's criteria as a Hispanic-serving Institution. Please visit www.nova.edu for more information about NSU and realizingpotential.nova.edu for more information on the largest fundraising campaign in NSU history.


Nathwani A.C.,University College London | Nathwani A.C.,Royal Free London NHS Foundation Trust Hospital | Nathwani A.C.,National Health Services Blood and Transplant | Down J.F.,University College London | And 8 more authors.
The Lancet | Year: 2016

Background Polonium-210 (210Po) gained widespread notoriety after the poisoning and subsequent death of Mr Alexander Litvinenko in London, UK, in 2006. Exposure to 210Po resulted initially in a clinical course that was indistinguishable from infection or exposure to chemical toxins, such as thallium. Methods A 43-year-old man presented to his local hospital with acute abdominal pain, diarrhoea, and vomiting, and was admitted to the hospital because of dehydration and persistent gastrointestinal symptoms. He was initially diagnosed with gastroenteritis and treated with antibiotics. Clostridium difficile toxin was subsequently detected in his stools, which is when he first raised the possibility of being poisoned and revealed his background and former identity, having been admitted under a new identity with which he had been provided on being granted asylum in the UK. Within 6 days, the patient had developed thrombocytopenia and neutropenia, which was initially thought to be drug induced. By 2 weeks, in addition to bone marrow failure, he had evidence of alopecia and mucositis. Thallium poisoning was suspected and investigated but ultimately dismissed because blood levels of thallium, although raised, were lower than toxic concentrations. The patient continued to deteriorate and within 3 weeks had developed multiple organ failure requiring ventilation, haemofiltration, and cardiac support, associated with a drop in consciousness. On the 23rd day after he first became ill, he suffered a pulseless electrical activity cardiorespiratory arrest from which he could not be resuscitated and was pronounced dead. Findings Urine analysis using gamma-ray spectroscopy on day 22 showed a characteristic 803 keV photon emission, raising the possibility of 210Po poisoning. Results of confirmatory analysis that became available after the patient's death established the presence of 210Po at concentrations about 109-times higher than normal background levels. Post-mortem tissue analyses showed autolysis and retention of 210Po at lethal doses in several organs. On the basis of the measured amounts and tissue distribution of 210Po, it was estimated that the patient had ingested several 1000 million becquerels (a few GBq), probably as a soluble salt (eg, chloride), which delivered very high and fatal radiation doses over a period of a few days. Interpretation Early symptoms of 210Po poisoning are indistinguishable from those of a wide range of chemical toxins. Hence, the diagnosis can be delayed and even missed without a high degree of suspicion. Although body surface scanning with a standard Geiger counter was unable to detect the radiation emitted by 210Po, an atypical clinical course prompted active consideration of poisoning with radioactive material, with the diagnosis ultimately being made with gamma-ray spectroscopy of a urine sample. Funding UK NHS, Public Health England, and the UK Department of Health. © 2016 Elsevier Ltd


Receive press releases from iHealthcareAnalyst, Inc.: By Email Metabolomics Market USD 1.24 Billion by 2020, Published by iHealthcareAnalyst, Inc. Maryland Heights, MO, November 03, 2016 --( Visit the Metabolomics Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/ Metabolomics is the scientific study of chemical processes involving metabolites, whereas metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes. mRNA gene expression data and proteomic analyses reveal the set of gene products being produced in the cell, data that represents one aspect of cellular function including systems biology and functional genomics that integrates proteomic, transcriptomic, and metabolomic information to provide a better understanding of cellular biology. The metabolomics market report estimates the market size (Revenue USD million - 2013 to 2020) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global metabolomics market including company overview, financial snapshot, key products, technologies and services offered, and recent trends in strategic management. The global metabolomics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. 1. Technique 1.1. Detection Techniques 1.2. Separation Techniques 2. Application 2.1. Biomarker Discovery 2.2. Clinical Toxicology 2.3. Drug Assessment 2.4. Nutrigenomics 3. Company Profiles 3.1. Agilent Technologies Inc. 3.2. Biocrates Life Sciences AG 3.3. Bio-Rad Laboratories, Inc. 3.4. Bruker Corporation 3.5. Human Metabolome Technologies Inc. 3.6. LECO Corporation 3.7. Metabolon Inc. 3.8. Shimadzu Corporation 3.9. ThermoFisher Scientific Inc. 3.10. Waters Corporation About Us iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareranalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, November 03, 2016 --( PR.com )-- The global metabolomics market is estimated to reach USD 1.24 Billion in 2020, growing at a CAGR of 15.6% from 2016 to 2020, according to a market research report Metabolomics Market 2013-2020, published by iHealthcareAnalyst, Inc.Visit the Metabolomics Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/Metabolomics is the scientific study of chemical processes involving metabolites, whereas metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes. mRNA gene expression data and proteomic analyses reveal the set of gene products being produced in the cell, data that represents one aspect of cellular function including systems biology and functional genomics that integrates proteomic, transcriptomic, and metabolomic information to provide a better understanding of cellular biology.The metabolomics market report estimates the market size (Revenue USD million - 2013 to 2020) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global metabolomics market including company overview, financial snapshot, key products, technologies and services offered, and recent trends in strategic management.The global metabolomics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.1. Technique1.1. Detection Techniques1.2. Separation Techniques2. Application2.1. Biomarker Discovery2.2. Clinical Toxicology2.3. Drug Assessment2.4. Nutrigenomics3. Company Profiles3.1. Agilent Technologies Inc.3.2. Biocrates Life Sciences AG3.3. Bio-Rad Laboratories, Inc.3.4. Bruker Corporation3.5. Human Metabolome Technologies Inc.3.6. LECO Corporation3.7. Metabolon Inc.3.8. Shimadzu Corporation3.9. ThermoFisher Scientific Inc.3.10. Waters CorporationAbout UsiHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareranalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


News Article | March 30, 2016
Site: www.rdmag.com

Researchers have taken major steps in drug analysis. While medication is often prescribed as a way to relieve the stresses and traumas following combat, more than 20 percent of military people with post-traumatic stress disorder have developed a drug or alcohol addiction. Although there are treatments for substance dependence, including medication to reduce its use (Buprenorphine), tests performed by Veterans Affairs hospital physicians that check for recurring drug use usually involve collecting urine samples and sending to a lab for analysis, which could take up to two weeks. But now you don’t have to wait that long. In fact, you could get test results while the individual is still in the VA hospital so that treatment can be quickly adjusted. Real-Time Analyzers Inc. has been developing a surface-enhanced Raman spectroscopy (SERS)-based assay that can detect and identify numerous drugs in saliva at ng/mL concentrations within 10 minutes. The sample collection from subjects began in August 2015 and is ongoing. While the first field-usable Raman spectrometer was developed more than a decade ago, today the company uses a hand-held version to measure the drugs in saliva. The Connecticut-based company that designs and manufactures Raman analyzers for use in field, plant and laboratory settings partnered with CT Veterans Affairs Hospital, so all of its subjects were in fact military personnel. “The goal is to try and help our veterans reduce their addiction to the drugs that they started taking when they were in the field,” Stuart Farquharson, Ph.D., Board of Directors member & president at Real-Time Analyzers told R&D Magazine after his session at Pittcon in Atlanta earlier this month, titled Clinical Toxicology: Analysis of Drugs in Saliva During Treatment of PTSD Patients. “To do that, we need to monitor that they’re taking the drugs that are trying to help them and that’s been the biggest issue, we need a point-of-care measurement so you know what the situation is when the doctor is talking to them each time they visit.” Co-authors of this study also included Katie Dana, Chetan Shende and Dr. Albert Arias. According to the Substance Abuse and Mental Health Services Administration, 23.9 million Americans currently use illicit drugs, and 6.8 million Americans misuse prescription drugs. The most common drugs prescribed to PTSD patients are Benzodiazepines and an addictive anxiety medication called Diazepam. As a result, the SERS analyzer was developed to provide the following: Real-Time Analyzers used the portable drug analyzer by collecting 1 mL of saliva, added a sample of reagent tube, passed the sample through a filter into Lab-on-chip, then inserted the LOC into the portable Raman analyzer. The device extracted drugs using SLE. The team measured 150 drugs, looking for the standard ones of abuse, such as cocaine and prescription drugs. The researchers also developed a spectral search and match software to ID the drugs found in the subject’s saliva. “In the end we were able to get a measurement that was pretty consistent,” Farquharson said during the session. The research team’s findings were “shocking,” according to Farquharson—of the more than 100 samples measured, very few of them had any drugs at all in their system, save for “street drugs.” “That’s another part of the scenario—they (veterans) are selling the medication they’re using to get other drugs, which is really unfortunate,” he added. While the research team achieved the required 10-50 nanograms/mL sensitivity for many of the drugs in water samples, they still need to improve the extraction method to obtain the same sensitivity in saliva samples. “Our goal is to have an analyzer and method that can identify and quantify drugs in saliva within 10 minutes of sample collection. This would provide doctors with the ability to evaluate PTSD patients during office visits. The analyzer would also allow rapid identification of drug type in emergency-room overdose patients,” Farquharson concluded. Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community! Learn more.


News Article | August 22, 2016
Site: www.sciencenews.org

For some people, fentanyl can be a life-saver, easing profound pain. But outside of a doctor’s office, the powerful opioid drug is also a covert killer. In the last several years, clandestine drugmakers have begun experimenting with this ingredient, baking it into drugs sold on the streets, most notably heroin. Fentanyl and closely related compounds have “literally invaded the entire heroin supply,” says medical toxicologist Lewis Nelson of New York University Langone Medical Center. Fentanyl is showing up in other drugs, too. In San Francisco’s Bay Area in March, high doses of fentanyl were laced into counterfeit versions of the pain pill Norco. In January, fentanyl was found in illegal pills sold as oxycodone in New Jersey. And in late 2015, fentanyl turned up in fake Xanax pills in California. This ubiquitous recipe-tinkering makes it impossible for users to know whether they’re about to take drugs mixed with fentanyl. And that uncertainty has proved deadly. Fentanyl-related deaths are rising sharply in multiple areas. National numbers are hard to come by, but in many regions around the United States, fentanyl-related fatalities have soared in recent years. Maryland is one of the hardest-hit states. From 2007 to 2012, the number of fentanyl-related deaths hovered around 30 per year. By 2015, that number had grown to 340. A similar rise is obvious in Connecticut, where in 2012, there were 14 fentanyl-related deaths. In 2015, that number was 188. In Massachusetts, two-thirds of people who died from opioid overdoses in the first half of 2016 showed signs of fentanyl. This wave of fentanyl-related overdoses is “horrendous,” says Daniel Ciccarone of the University of California, San Francisco. What’s worse, he says, “I think it’s here to stay.” Fentanyl is not a new drug. Available in the 1960s, it is still used in hospitals as an anesthetic and is available by prescription to fight powerful pain. What’s new, Ciccarone says, is that clandestine drug manufacturers have discovered that the euphoria-producing opioid can be made cheaply and easily — no poppy fields necessary. Fentanyl is about 30 to 40 times stronger than heroin and up to 100 times more powerful than morphine, which means that a given effect on the body can be achieved with a much smaller amount of fentanyl. Inadvertently taking a bit of fentanyl can cause big trouble. “It’s a dosing problem,” Nelson says. “Because the drug is so potent, little changes in measurements can have very big implications for toxicity. That’s really the problem.” That problem is made worse by the variability of illegal drugs — users often don’t know what they’re buying. Illegal labs aren’t pumping out products with carefully calibrated doses or uniform chemical makeup. The drugs change from day to day, making it nearly impossible for a user to know what he or she is about to take, Ciccarone says. He has seen this struggle up close. Drug users have told him that the products they buy are unpredictable. Another thing people are telling him: “That they and their friends and compatriots are dropping like flies.” Tellingly, some of the most experienced drug users have recently begun doing “tester shots,” small doses to get a sense of the type and dose of drug they’re about to use, Ciccarone says. Users are right to be wary. Typically, opioids can kill by gradually depressing a person’s ability to breathe. Illicit fentanyl, a recent study suggests, can kill within minutes by paralyzing muscles. Doctors have known that when injected quickly, fentanyl can paralyze chest wall muscles, prevent breathing and kill a person rapidly. That effect, called “wooden chest,” might help explain the rise in fentanyl-related deaths, scientists report in the June Clinical Toxicology. A quick injection of fentanyl “literally freezes the muscles and you can’t move the chest,” says toxicologist Henry Spiller of the Central Ohio Poison Center in Columbus. That’s why doctors who dispense fentanyl in the hospital intentionally proceed very slowly and keep the opioid-counteracting drug naloxone (Narcan) on hand. “If you give it too fast, we know this occurs,” Spiller says. But it wasn’t known whether this same phenomenon might help explain the death rate of people using the drug illegally. Spiller and colleagues tested post-mortem concentrations of fentanyl and its breakdown product norfentanyl in 48 fentanyl-related deaths. The body usually begins breaking down fentanyl into norfentanyl within two minutes, an earlier study found. Yet in 20 of the cases, the researchers found no signs of norfentanyl, indicating death came almost immediately after first receiving fentanyl. Naloxone can counteract the effects of opioids if someone nearby can administer the antidote. But for people whose chests quickly freeze from fentanyl, resuscitation becomes more unlikely. Fentanyl “is just a bad drug,” Spiller says. Fentanyl’s danger is magnified for people not accustomed to taking opioids, such as those addicted to cocaine, a situation illustrated by a recent tragedy in New Haven, Conn. New Haven authorities noticed a string of suspicious overdoses in late June, leaving three people dead. Drug users thought they were buying cocaine, but the drugs contained fentanyl, says analytical toxicologist Kara Lynch of the University of California, San Francisco. As one of the handful of labs capable of testing blood and urine for fentanyl, hers was called on to identify the culprit. Her lab spotted fentanyl in Norco tablets back in March. Lynch’s group uses high-resolution mass spectrometry to detect many drugs’ chemical signatures. But this method reveals only the drugs scientists suspect. “We can look for what we know to look for,” she says. And success depends on getting the samples in the first place. The logistical hurdles of figuring out exactly what a person took, and how much, and when, are large. Ciccarone contrasts the situation with cases of food poisoning. When people start getting sick, public health officials can figure out what lettuce people ate and test it for pathogens. The same kind of tracking system doesn’t exist for drugs. His efforts to develop a system for testing illegal drugs in Baltimore broke down in part because no one had time to do the work. “The coroner is so busy right now with dead bodies,” he says. “They don’t have the time to test the ‘lettuce.’ ” In the quest to curb fentanyl-related deaths, scientists and public health officials are searching for new strategies. Spiller advocates a more targeted public health message to users, one that emphasizes that fentanyl is simply a deadly drug, not just a more potent high. Ciccarone says that facilities where drug users can take illegal drugs under the care of medical personnel might reduce the number of fatalities. For now, the scope of the problem continues to grow, Nelson says. The situation is made worse by the ingenuity of illicit drugmakers, who readily experiment with new compounds. Fentanyl itself can be tweaked to create at least 16 related forms, one of which, acetyl fentanyl, has been linked to overdose deaths. New drugs and new tweaks to old drugs rapidly evolve (SN: 5/16/15, p. 22), Nelson says, creating a game of whack-a-mole in which designer drugs confound public health officials and law enforcement. “There is no single easy solution to this problem,” he says.


The diabetes monitoring, treatment and drug delivery market in the U.S. is expected to increase to over $25 billion by 2023 VANCOUVER, BC--(Marketwired - November 02, 2016) - According to a new series of reports on the U.S. market for diabetes monitoring, treatment and drug delivery by iData Research (www.idataresearch.com), growth in the U.S. diabetes market is expected to persist over the next several years. Growth will be driven by the increasing prevalence of diabetes in the U.S. and technological advancements made in certain segments, particularly insulin pumps and continuous glucose monitoring (CGM). However, lower reimbursement rates exhibit a significantly limiting effect on the market, as downward pressure is applied to pricing in the overall blood glucose monitoring market. "The recent influx of low-price competitors in the blood glucose test strip segment has placed downward pressure on prices," explains Dr. Kamran Zamanian, CEO of iData. "As a result, overall market value has decreased despite the increasing number of diabetics testing their blood glucose levels in the United States." In addition, patent expirations of flagship insulin products have resulted in the emergence of biosimilars or generic insulins, as well as next-generation insulins. Biosimilars are competitively priced to their insulin counterparts and put downward pressure on the overall price of insulin. Next-generation insulins are typically premium priced due to their increased average active durations, decreasing the amount of injections patients must perform on a daily basis. The Clinical Chemistry and Clinical Toxicology Devices panel of the FDA recently voted in favor of a non-adjunctive label that would allow DexCom G5® Mobile users to make insulin dosing decisions based on CGM data, as opposed to traditional blood glucose meter readings. Although some CGM users have already been making insulin dosing decisions based on their CGM data, attaching such a claim to the product would reinforce confidence in CGM accuracy and have significant implications for the future of the market. A non-adjunctive claim may increase the likelihood of Medicare patients, who represent nearly 40% of the total diagnosed diabetic population, receiving reimbursement for CGM products in the future. As a result, CGM penetration would be positively influenced by the increased accessibility and number of physicians who are more likely to prescribe CGM as a therapy option. Sanofi has the largest share of the diabetes monitoring, treatment and drug delivery market, due to their strong position in the insulin, prefilled pen and pen cartridge markets. Sanofi dominates the long-acting insulin segment with its flagship product, Lantus®, which has been available on the U.S. market since 2001. The patent for Lantus® expired in 2015 and is expected to face competition from a biosimilar product by Eli Lilly and Boehringer Ingelheim. In response, Sanofi is currently developing a biosimilar to Eli Lilly's popular rapid-acting insulin analog Humalog®. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets. More on the diabetes device market in the U.S. can be found in a series of reports published by iData Research entitled the US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery. The suite covers reports on the following markets: blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. The iData report series on diabetes devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about diabetes device market data or procedure data, register online or email us at info@idataresearch.net for a US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery brochure and synopsis. iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.

Loading Clinical Toxicology collaborators
Loading Clinical Toxicology collaborators